Top Market Research Companies in the USA (2026 Guide)

Leading market research firms in the USA include BioNixus, Kantar, Ipsos, NielsenIQ, YouGov, and Euromonitor International. BioNixus ranks first for pharmaceutical and healthcare research, operating as a global network headquartered in the US with full-service capability, IRB-compliant HCP and payer research, PBM formulary expertise, and 120+ global projects annually (127 in 2025) across 48 countries as of 2026.

Custom market research engagements in the USA typically range from $30,000 to $120,000 per project depending on scope, methodology, geography, and research complexity. Healthcare and pharmaceutical studies with IRB review requirements, specialist HCP recruitment, or PBM payer depth interviews cost more. Syndicated reports range from $2,500 to $15,000. Multi-region US programs (Northeast, South, Midwest, West Coast) add 20–30% versus single-region studies.

BioNixus specialises in pharmaceutical market research in the USA, covering IRB-compliant HCP surveys, KOL mapping across major academic medical centres, PBM payer research, CMS coverage intelligence, IRA drug negotiation impact studies, and HEOR evidence generation. Ipsos and Kantar also operate healthcare divisions with varying US pharmaceutical-specific depth.

BioNixus combines both — US headquarters with global network reach (48 countries, 118 global clients) alongside deep US-specific pharmaceutical capability including IRB compliance, PBM payer research, AMC physician access, and IRA intelligence. Global networks like Kantar and Ipsos offer large panel infrastructure and global benchmarking; pharmaceutical clients typically choose BioNixus for global standards with genuine US pharmaceutical depth.

A mixed-method design typically delivers the most commercially actionable US pharmaceutical insights. BioNixus combines quantitative HCP surveys (CATI, online physician panels), qualitative in-depth interviews (KOL and payer IDIs), virtual advisory boards, and paired physician-payer modules. Method selection is guided by the decision question: launch readiness may require physician quant plus payer depth interviews; market access strategy prioritizes PBM committee interviews and ICER pre-assessment research.

The US multi-payer system fundamentally shapes pharmaceutical commercial strategy. FDA approval grants market authorisation but not commercial access. PBM formulary placement (UnitedHealth/Optum, CVS/Caremark, Express Scripts) determines commercial insurance access; CMS Medicare Part B/D coverage determines government payer access; GPO pricing contracts affect hospital supply chain penetration. The IRA's Medicare price negotiation (effective 2026) has added a new strategic layer for products with Medicare exposure. Market research must account for all these payer dynamics.

Yes. US pharmaceutical and patient research increasingly requires multilingual instruments — Spanish for Hispanic patient populations, Mandarin and Cantonese for Asian-American patient segments, and additional languages for diverse physician communities in major US cities. BioNixus supports multilingual US studies with culturally adapted instruments reviewed for clinical accuracy.

Key criteria include: (1) US pharmaceutical research experience with IRB compliance track record, (2) verified HCP recruitment at major AMCs and community practices, (3) PBM and CMS payer research capability, (4) IRA and FDA regulatory context built into study design, (5) data integrity controls and respondent verification, (6) therapy-area depth in your specific category, and (7) ability to connect findings to launch, market access, or commercial decisions. Request case study summaries and IRB documentation.